Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Apr 11, 2024 Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Apr 10, 2024 Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 Apr 08, 2024 Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform Apr 05, 2024 Theratechnologies Appoints Elina Tea to its Board of Directors Apr 03, 2024 Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update Mar 28, 2024 Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform Mar 22, 2024 Theratechnologies Announces Update on its Preclinical Oncology Research Program Mar 21, 2024 Theratechnologies Appoints Jordan Zwick to its Board of Directors Mar 21, 2024 Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer Feb 29, 2024 Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 21 - 30 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Apr 11, 2024 Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Apr 10, 2024 Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Apr 08, 2024 Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
Apr 03, 2024 Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
Mar 28, 2024 Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
Mar 21, 2024 Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
